DR

VergeIO Introduces ioGuardian: Revolutionizing Backup and Recovery for Unprecedented Data Integrity and Accessibility

Retrieved on: 
Tuesday, March 12, 2024
Software, Technology, Data Management, RAM, DR, Face, Running, RPO, VMS, Overalls, Computer data storage

ioGuardian sets a new standard for backup and recovery processes by offering inline recovery capabilities, ensuring near-continuous data access without the need for traditional recovery timeframes.

Key Points: 
  • ioGuardian sets a new standard for backup and recovery processes by offering inline recovery capabilities, ensuring near-continuous data access without the need for traditional recovery timeframes.
  • Unlike conventional backup appliances that require significant downtime for data recovery, ioGuardian delivers missing data segments to virtual machines (VMs) in real time.
  • While some backup solutions offer instant recovery by restarting VMs on a backup appliance, ioGuardian's inline recovery nearly eliminates downtime.
  • By integrating advanced backup and recovery functionalities directly into VergeOS, we are setting new benchmarks for data protection and accessibility in the industry.

EQS-News: FYB201/Ranibizumab keeps gaining momentum with approvals and launches in the MENA region

Retrieved on: 
Wednesday, March 13, 2024
Diabetes, Paratriathlon, Eye, Blood, Retina, Biosimilar, Gulf Cooperation Council, GCC, Ranibizumab, Prevalence, DR, Health, VEGF, Macular degeneration, Patient, NAMD, DME, CBO, Visual impairment, Partnership, Pharmaceutical industry

In addition, further market launches are planned in Algeria and other Gulf Cooperation Council (GCC) markets over the course of 2024.

Key Points: 
  • In addition, further market launches are planned in Algeria and other Gulf Cooperation Council (GCC) markets over the course of 2024.
  • This strategic collaboration aims to improve access to ophthalmic treatments in the MENA region.
  • Biosimilar and specialty medicines are integral to MS Pharma product portfolio and play a crucial role in advancing our growth objectives in the MENA region.
  • This approval supports the company's commitment to the Saudi market and its broader strategic initiatives within the kingdom."

Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update

Retrieved on: 
Friday, March 8, 2024
OCUP, Research, Mydriasis, FDA, Protocol, PS, Presbyopia, Calendar, Diabetic retinopathy, Interim, Safety, DR, Diabetes, Patient, SPA, Security (finance), Ash, LPC, Pharmaceutical industry

In October 2023, Ocuphire held an End-of-Phase 2 meeting with the FDA and aligned on the registrational primary endpoint of 3-step or more worsening on binocular DRSS Person scale.

Key Points: 
  • In October 2023, Ocuphire held an End-of-Phase 2 meeting with the FDA and aligned on the registrational primary endpoint of 3-step or more worsening on binocular DRSS Person scale.
  • In February 2024, Ocuphire submitted a Special Protocol Assessment (“SPA”) to seek agreement on the clinical trial protocol and statistical analysis plan for Phase 3.
  • In September 2023, Ocuphire and Viatris, Inc. (“Viatris”) announced FDA approval of PS under the brand name RYZUMVI™ for the treatment of pharmacologically-induced mydriasis.
  • Financial Highlights for the Fourth Quarter and Full Year Ended December 31, 2023
    As of December 31, 2023, Ocuphire had cash and cash equivalents of approximately $50.5 million.

EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet

Retrieved on: 
Friday, March 8, 2024
FACS, Regeneron Pharmaceuticals, Research, HD, Food, Floater, Cataract, Consultant, Aflibercept, Diabetic retinopathy, European, Intraocular pressure, Safety, DR, Society, Retinal, Bayer, Diabetes, Patient, Publication, Pharmaceutical industry

TARRYTOWN, N.Y., March 08, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced The Lancet published one-year results from the pivotal PULSAR and PHOTON trials for EYLEA® HD (aflibercept) Injection 8 mg. Specifically, the publications detailed data demonstrating that EYLEA HD extended dosing regimens were non-inferior to EYLEA® (aflibercept) Injection 2 mg for both the treatment of wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).

Key Points: 
  • Specifically, the publications detailed data demonstrating that EYLEA HD extended dosing regimens were non-inferior to EYLEA® (aflibercept) Injection 2 mg for both the treatment of wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).
  • “Less than a year after its approval, EYLEA HD has already made an impact in the treatment of wet age-related macular degeneration and diabetic macular edema.
  • EYLEA HD has provided disease control for my tough-to-treat cases of diabetic eye disease and allowed both my diabetic and wet age-related macular degeneration patients to enjoy less frequent dosing with a similar safety profile to EYLEA.”
    PULSAR and PHOTON are two double-masked, active-controlled pivotal trials evaluating EYLEA HD compared to EYLEA.
  • In the U.S., Regeneron maintains exclusive rights to EYLEA and EYLEA HD.

HLTH Foundation honors Vision Loss Rehabilitation Canada for advancing AI-enabled healthcare in underserved communities

Retrieved on: 
Wednesday, February 28, 2024
Health Canada, Doctor of Philosophy, LOS, AI, Health, Language, Paratriathlon, Diabetic retinopathy, DR, Organization, Patient, Disease, Face, Medical device

The HLTH Foundation's Techquity for Health Coalition issued the award after reviewing over 200 case study submissions from around the world.

Key Points: 
  • The HLTH Foundation's Techquity for Health Coalition issued the award after reviewing over 200 case study submissions from around the world.
  • Using AI, VLRC is making significant advancements in improving access to critical vision care, particularly in rural, remote, and Indigenous communities across Ontario.
  • "This recognition of Vision Loss Rehabilitation Canada is well deserved for their continuing success in bringing vision-saving eye care to rural and Indigenous communities," said Kaushal Solanki, PhD, founder and CEO of Eyenuk.
  • The HLTH Foundation, a 501(c)3 non-profit of HLTH, Inc., promotes equity, inclusion and opportunity in healthcare, focusing on patients, healthcare professionals and startup founders.

Good Design Awards Honors Multiple Products from Generac

Retrieved on: 
Monday, February 5, 2024
Generac, AC, Electronics, Noise, Transport, DR, Industrial, USB, GOOD

WAUKESHA, Wis., Feb. 5, 2024 /PRNewswire/ -- Generac Power Systems, Inc., (NYSE: GNRC) a leading global designer and manufacturer of energy technology solutions and other power products, today announced it has received five accolades from the 2023 GOOD DESIGN Awards in the Building Materials category. 

Key Points: 
  • WAUKESHA, Wis., Feb. 5, 2024 /PRNewswire/ -- Generac Power Systems, Inc., (NYSE: GNRC) a leading global designer and manufacturer of energy technology solutions and other power products, today announced it has received five accolades from the 2023 GOOD DESIGN Awards in the Building Materials category.
  • Celebrating its 73rd anniversary, the GOOD DESIGN Awards program is one of the oldest design competitions in the world.
  • "It is an honor to be recognized by the GOOD DESIGN Awards.
  • For more information about the GOOD DESIGN Awards, please visit the official website: https://www.good-designawards.com/

Three Journal of Pharmaceutical Analysis Studies Explore the Use of Traditional Chinese Medicine for Various Diseases

Retrieved on: 
Friday, January 26, 2024
DMY, Microangiopathy, Neoplasm, VEGF, NAFLD, Radiation, Fe, ATGL, Disease, Lung cancer, TCM, DR, Risk, Quality of life, Diabetic retinopathy, Journal, Nano, Traditional Chinese medicine, Liver, Noetics, Protein, HSP90, CDC37, Non-alcoholic fatty liver disease, Iron

XI'AN, China, Jan. 26, 2024 /PRNewswire/ -- Despite demonstrating significant clinical efficacy against various diseases, the widespread use of Traditional Chinese Medicine (TCM) is still limited.

Key Points: 
  • XI'AN, China, Jan. 26, 2024 /PRNewswire/ -- Despite demonstrating significant clinical efficacy against various diseases, the widespread use of Traditional Chinese Medicine (TCM) is still limited.
  • To address this gap, a new issue of the Journal of Pharmaceutical Analysis presents three independent studies which assessed the potency of TCM-based compounds for various human diseases, along with their molecular mechanisms of action.
  • Oridonin (ORI), a TCM derived from the Chinese herb Rabdosia rubescens, exhibits anti-inflammatory effects.
  • These studies provide a scientific basis for the development of TCM-based compounds into effective targeted therapies for various diseases.

Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report

Retrieved on: 
Monday, January 8, 2024
GEJ, Immunoglobulin A, GPRC5D, Government, Trastuzumab, Daiichi Sankyo, DME, BRCA, FDA, Spacecraft, Health, Haemophilia, Abiraterone acetate, Infection, PDE, Crohn's disease, CLVT, Drug discovery, Breast cancer, Breast, Data, Budesonide, AMD, PARP, Metastasis, PDE4, DXD, Safety, NSCLC, Health care, RSV, DR, AstraZeneca, EMA, CRISPR, Chronic obstructive pulmonary disease, Adenocarcinoma, Multiple myeloma, Civil service commission, Artificial intelligence, Patient, Stada Arzneimittel, Intelligence, CD3, Ulcerative colitis, SCD, Lung cancer, European Commission, Sickle cell disease, Gilead Sciences, Respiratory syncytial virus, Research, Diabetic retinopathy, Mirikizumab, COPD, COVID-19, Conditional sentence, Genentech, Thalassemia, Organization, Zolbetuximab, ADC, Pharmaceutical industry

LONDON, Jan. 8, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announced the release of its annual Drugs to Watch™ report. The report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success. The report, a key industry resource in the evolving healthcare landscape, has identified over 85 Drugs to Watch over the 11-year course of its publication.

Key Points: 
  • The report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success.
  • The report, a key industry resource in the evolving healthcare landscape, has identified over 85 Drugs to Watch over the 11-year course of its publication.
  • Leveraging deep industry expertise and comprehensive therapeutic area differentiated data, this year's Drugs to Watch report identifies innovative medicines based on recent scientific breakthroughs poised to have extraordinary impacts on patient outcomes."
  • Included in Drugs to Watch 2023, a delayed U.S. launch meant that it remains a drug to watch for 2024.

Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report

Retrieved on: 
Monday, January 8, 2024
GEJ, Immunoglobulin A, GPRC5D, Government, Trastuzumab, Daiichi Sankyo, DME, BRCA, FDA, Spacecraft, Health, Haemophilia, Abiraterone acetate, Infection, PDE, Crohn's disease, CLVT, Drug discovery, Breast cancer, Breast, Data, Budesonide, AMD, PARP, Metastasis, PDE4, DXD, Safety, NSCLC, Health care, RSV, DR, AstraZeneca, EMA, CRISPR, Chronic obstructive pulmonary disease, Adenocarcinoma, Multiple myeloma, Civil service commission, Artificial intelligence, Patient, Stada Arzneimittel, Intelligence, CD3, Ulcerative colitis, SCD, Lung cancer, European Commission, Sickle cell disease, Gilead Sciences, Respiratory syncytial virus, Research, Diabetic retinopathy, Mirikizumab, COPD, COVID-19, Conditional sentence, Genentech, Thalassemia, Organization, Zolbetuximab, ADC, Pharmaceutical industry

LONDON, Jan. 8, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announced the release of its annual Drugs to Watch™ report. The report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success. The report, a key industry resource in the evolving healthcare landscape, has identified over 85 Drugs to Watch over the 11-year course of its publication.

Key Points: 
  • The report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success.
  • The report, a key industry resource in the evolving healthcare landscape, has identified over 85 Drugs to Watch over the 11-year course of its publication.
  • Leveraging deep industry expertise and comprehensive therapeutic area differentiated data, this year's Drugs to Watch report identifies innovative medicines based on recent scientific breakthroughs poised to have extraordinary impacts on patient outcomes."
  • Included in Drugs to Watch 2023, a delayed U.S. launch meant that it remains a drug to watch for 2024.

OcuTerra Therapeutics Announces Last Patient Completes Final Visit in Nesvategrast (OTT166) Eye Drop Phase 2 DR:EAM Clinical Trial in Diabetic Retinopathy

Retrieved on: 
Wednesday, January 3, 2024
Biotechnology, Diabetes, Pharmaceutical, Health, DRSS, RGD, DR, Diabetic retinopathy, Paratriathlon, Injection, Disease, Therapy, Clinical trial, PDR, Patient

Nesvategrast, OcuTerra’s novel, selective RGD integrin inhibitor delivered via eye drop, is being developed as a possible treatment for the millions of patients with diabetic retinopathy who currently have no active, non-invasive therapies approved for this potentially devastating disease.

Key Points: 
  • Nesvategrast, OcuTerra’s novel, selective RGD integrin inhibitor delivered via eye drop, is being developed as a possible treatment for the millions of patients with diabetic retinopathy who currently have no active, non-invasive therapies approved for this potentially devastating disease.
  • These data will show the percentage of patients that have a ≥2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) when treated with nesvategrast vs. placebo.
  • The 24-week study enrolled 225 adult patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) or mild proliferative diabetic retinopathy (PDR) with minimal vision loss.
  • We are excited to begin planning the next phase of development for nesvategrast.”